AMENDMENTS TO THE CLAIMS

1. (Original) A compound of general formula (I),



(I) (I)

any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein Q is $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$; one of R^1 and R^2 is $-CH_2-CH_2-CH_2-R^3$, $-CH_2-CH=CH-R^3$, or $-CH_2-C\equiv C-R^3$; wherein R^3 is aryl or heteroaryl; which aryl and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of: halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl; and the other of R^1 and R^2 is $-CO-R^4$; wherein R^4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl.

2. (Original) The compound according to claim 1, wherein Q is $-CH_2-CH_2-$.

3. (Original) The compound according to claim 1, wherein Q is $-CH_2-CH_2-CH_2-$.

4. (Previously Presented) The compound according to claim 1, wherein one of R^1 and R^2 is $-CH_2-CH=CH-R^3$; wherein R^3 is defined as in claim 1.

5. (Previously Presented) The compound according to claim 1, wherein R^4 is alkyl.

6. (Original) The compound according to claim 1, wherein Q is $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$; one of R^1 and R^2 is $-CH_2-CH=CH-R^3$, or $-CH_2-C\equiv C-R^3$; wherein R^3 is phenyl; and the other of R^1 and R^2 is $-CO-R^4$; wherein R^4 is alkyl.

7. (Currently Amended) A compound of claim 1, which is (±)-1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; (±)-1-[10-(3-Phenyl-allyl)-3,10-diaza bicyclo[4.3.1]dec-3-yl]-propan-1-one; ~~(±)-1-[3-(3-Phenyl-allyl-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one~~ (±)-1-[3-(3-Phenyl-allyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one; or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

8. (Previously Presented) A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

9. (Currently Amended) A method for treatment~~, prevention~~ or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to ~~responsive to~~ modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof; wherein the disease, disorder or condition responsive to modulation of the opioid receptor is pain.

10. (Cancelled)

11. (New) The method according to claim 9, wherein said pain is postoperative pain, chronic pain, cancer pain, neuropathic pain or pain during labor and delivery.